Research Peptides: US Regulatory Overview

This page is general information, not legal advice. It summarizes publicly available US federal materials as of the last-updated date shown (September 30, 2026). Laws, agency policies, and enforcement priorities change. For advice about a specific situation, consult a qualified attorney.

“Are research peptides legal?” is one of the most searched questions in this field, and it does not have a one-word answer. US law does not treat “research peptide” as a legal category. Instead, the legal status of a given material depends on what it is, how it is labeled and marketed, who buys it, and what it is intended for.

This overview explains the main pieces of the US federal framework, how FDA has applied them to peptide sellers, where the 2026 compounding review stands, and what advertising, state, and anti-doping rules add.

What “Research Use Only” Means

Where the Phrase Comes From

The phrase “For Research Use Only” has a specific origin in FDA regulations for in vitro diagnostic (IVD) products. Under 21 CFR 809.10(c), an IVD product in the laboratory research phase of development, and not represented as an effective diagnostic product, must bear the statement “For Research Use Only. Not for use in diagnostic procedures.”

FDA’s guidance on RUO and investigational-use-only IVD products describes this labeling as a warning meant to keep such products out of clinical diagnosis and patient management (FDA guidance).

How the Phrase Is Used for Peptides

Suppliers of research peptides and other laboratory reagents use the same phrase more broadly to state that a material is supplied for laboratory research, and is not a drug, food, cosmetic, or dietary supplement, and not for human or veterinary use. That is how A&A Wellness uses it; see our research-use policy.

The key point: an RUO statement communicates the supplier’s stated purpose. It does not, on its own, decide how regulators classify a product.

FDA’s Intended-Use Standard

The Regulation

Whether something is regulated as a drug depends heavily on its intended use. FDA’s regulation at 21 CFR 201.128 defines intended use as the objective intent of the persons legally responsible for labeling. That intent may be shown by labeling claims, advertising matter, oral or written statements, and the circumstances surrounding distribution.

How FDA Has Applied It to Peptide Sellers

FDA has issued warning letters to online peptide sellers that relied on research-use disclaimers. In a February 2025 letter, FDA wrote that despite statements such as “research use only,” “not for human consumption,” and “lab purposes only,” evidence from the seller’s website established that certain products were “drugs intended for human use” (FDA, 2025).

In an August 24, 2026 letter to another seller, FDA pointed to therapeutic claims in product descriptions and also noted that the seller marketed bacteriostatic water as a solvent for reconstituting its products, “thus, providing the means to prepare an injectable drug for human administration” (FDA, 2026).

FDA has also stated publicly that it has warned companies that sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide, or mazdutide that were “falsely labeled ‘for research purposes’ or ‘not for human consumption’” and sold to consumers with dosing instructions (FDA).

What This Means in Practice

Across these letters, FDA looked at the whole of each seller’s conduct. Recurring factors included:

• Disease or health claims in product descriptions
• Dosing guidance or references to human use
• Marketing aimed at consumers rather than laboratories
• Supplying the means to prepare a product for human administration

A research supplier that wants its RUO statement to be credible has to behave consistently with it everywhere: product copy, education content, customer communications, and packaging.

Approved Drugs vs Research Materials

Some research compounds share a name with the active ingredient in an FDA-approved prescription medicine. Tirzepatide and tesamorelin are examples. Others, such as retatrutide, are investigational and not approved for any use.

A research material is not the approved medicine, even when the compound name is the same. Approved drugs are manufactured, tested, labeled, and distributed under a framework that does not apply to research reagents. FDA states that retatrutide “cannot be used in compounding under federal law,” is not a component of any FDA-approved drug, and has “not been found safe and effective for any condition” (FDA).

For compound-level detail, see our GLP-1 class comparison and growth hormone secretagogues overview.

Compounding and the Bulk Drug Substance Lists

Compounding rules govern licensed pharmacies and outsourcing facilities, not research-reagent suppliers. They are still worth understanding, because FDA’s compounding decisions are the agency’s most detailed public statements on many individual peptides.

How Section 503A Works

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacy may compound using a bulk drug substance only if it meets one of three conditions: it complies with an applicable USP or NF monograph, it is a component of an FDA-approved drug, or it appears on FDA’s 503A bulks list (FDA).

FDA’s Interim Categories

While nominations are evaluated, FDA sorts nominated substances into interim categories:

• Category 1: sufficient supporting information; FDA does not intend to take action against compounders using these substances if conditions are met.
• Category 2: FDA has identified significant safety risks and would consider taking action against compounders using them.
• Category 3: nominated with insufficient information.

Where Specific Peptides Stand

FDA’s page on bulk drug substances that may present significant safety risks (content current as of April 22, 2026) includes the following (FDA):

• Listed in category 2 (examples relevant to peptide research): ipamorelin acetate (for 503B outsourcing facilities), GHRP-2, GHRP-6, ibutamoren mesylate, and kisspeptin-10.
• Nominated but withdrawn from category 2 by the nominators: substances including BPC-157, CJC-1295, Selank acetate, Semax, the thymosin beta-4 fragment associated with TB-500, GHK-Cu (injectable routes), KPV, and MOTs-C.

Withdrawal from category 2 does not mean a substance was approved or placed on the bulks list.

The 2026 Advisory Committee Review

On April 16, 2026, FDA published a Federal Register notice announcing a meeting of its Pharmacy Compounding Advisory Committee (PCAC) and opening public docket FDA-2025-N-6895 on bulk drug substances nominated for the 503A list (Federal Register).

The committee met on July 23-24, 2026 and discussed seven substances, each for specific nominated uses (FDA):

Date	Substance	Use under discussion
July 23	BPC-157	Ulcerative colitis
July 23	KPV	Wound healing and inflammatory conditions
July 23	TB-500	Wound healing
July 23	MOTs-C	Obesity and osteoporosis
July 24	Emideltide (DSIP)	Opioid withdrawal, chronic insomnia, narcolepsy
July 24	Semax	Cerebral ischemia, migraine, trigeminal neuralgia
July 24	Epitalon	Insomnia

Trade press (AJMC, July 31, 2026) reported that the committee voted to recommend six of the seven for the 503A list and did not recommend emideltide. Advisory committee votes are non-binding. As of this page’s last update, we are not aware of FDA having completed action to add any of these substances to the 503A bulks list, and none is an FDA-approved drug. Check FDA’s pages directly for the current position.

For compound-specific context, see BPC-157 vs TB-500 and Selank vs Semax.

Advertising and the FTC

The Federal Trade Commission and FDA share jurisdiction over the marketing of health-related products. FDA has primary responsibility for claims in labeling, and the FTC has primary responsibility for claims in advertising.

The FTC’s Health Products Compliance Guidance (December 2022) explains that health-related claims must be truthful, not misleading, and supported by competent and reliable scientific evidence, generally meaning well-controlled human clinical testing for health benefit claims (FTC).

The practical consequence for research suppliers: the safest and most accurate position is not to make health or performance claims at all. A research supplier describes what a compound is and what published studies report, attributed to those studies. That is the approach we take across our education library.

State-Level Considerations

States regulate pharmacies, drug distribution, and consumer protection under their own laws, and some state boards of pharmacy and attorneys general have their own enforcement priorities for peptides. State rules can differ from federal rules and from one another.

Anyone buying, selling, or using research materials should consider the rules of their own state and of the states where materials are shipped. Institutional researchers should also follow their organization’s procurement, biosafety, and compliance policies.

Anti-Doping: WADA

The World Anti-Doping Agency’s Prohibited List applies to athletes in sport, not to laboratories, but it is a useful reference for how many research peptides are classified. The 2026 list, effective January 1, 2026, includes (WADA):

• S0, non-approved substances: any pharmacological substance with no current approval for human therapeutic use, naming BPC-157 as an example
• S2, peptide hormones and releasing factors: GHRH and its analogues (including CJC-1295, sermorelin, and tesamorelin), growth hormone secretagogues (including ipamorelin and ibutamoren), and GHRPs
• S2, growth factors: IGF-1 and its analogues, and “Thymosin-β4 and its derivatives e.g. TB-500”

How A&A Wellness Operates Within This Framework

• Every product is labeled and sold for research use only, and is not for human or veterinary use
• Our product pages and education content contain no dosing, protocols, or health claims
• Education pages describe compounds and attributed research findings, with citations
• Orders require a research-use acknowledgment
• Every product is guaranteed to meet 99% purity and is lab tested in the USA; see our Quality page

For how to evaluate any supplier against these standards, see how to vet a research peptide supplier.

Summary

• “Research use only” originated in FDA’s IVD labeling rules and is widely used for laboratory reagents, but it does not by itself determine a product’s legal status.
• FDA judges intended use from objective evidence, including labeling, advertising, and seller statements, and has cited RUO-labeled peptide sellers in warning letters.
• FDA’s compounding lists govern pharmacies. The 2026 advisory committee votes on seven peptides are non-binding and, as of this update, have not resulted in any listing.
• The FTC requires health claims in advertising to be substantiated; research suppliers should not make them.
• State laws and WADA rules add further layers.

This page is general information, not legal advice. Last updated September 30, 2026.